As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

Patients with lung cancer who have never smoked are usually diagnosed too late for curative treatment. Pam Dalrymple, ...

The collaboration between the two companies reflects ongoing efforts to enhance drug development, the CEO of Immunai said.

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...